Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerability and PK of Netanasvir Phosphate (HEC74647PA) in Healthy Adults
NCT03673696Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Sep 2018
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of antaitavir hasophate in hepatitis C (HCV) (9 arms), sponsored by Sunshine Lake Pharma. Primary endpoints: Adverse events of the single ascending-dose, Adverse events of the multiple ascending-dose and 7 more. Started Sep 2018; status: completed.
02
Drugs
antaitavir hasophate
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03673696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03673696.